FDA inspections continue to reveal recurring compliance gaps related to electronic records, electronic signatures, audit trails, and data integrity. While many pharmaceutical companies have implemented digital systems, regulators frequently identify weaknesses in how these systems are configured, validated, monitored, and controlled.
The objective of 21 CFR Part 11 is not simply to digitize records but to ensure that electronic records are trustworthy, secure, traceable, and equivalent to paper records.
This article explores the most common FDA audit findings related to 21 CFR Part 11 compliance and provides practical strategies to avoid them.
FDA investigators evaluate whether electronic systems adequately support:
Failure in any of these areas can result in observations, warning letters, compliance delays, and increased regulatory scrutiny.
Top 15 FDA Audit Findings Related to 21 CFR Part 11
Organizations cannot demonstrate who created, modified, or deleted records.
Risk
How to Avoid It
Implement systems that automatically capture:
Internal Resource:
https://vmtspharmasoftware.com/quality-management-system/
Multiple employees use the same login credentials.
Risk
Investigators cannot determine who performed specific actions.
How to Avoid It
Passwords never expire or fail to meet complexity requirements.
Risk
Unauthorized access to regulated records.
How to Avoid It
Establish:
Organizations cannot demonstrate that software performs as intended.
Risk
System-generated records become unreliable.
How to Avoid It
Maintain documented:
Electronic signatures are not uniquely linked to individual users.
Risk
Questionable record authenticity.
How to Avoid It
Ensure signatures are:
Employees use outdated SOPs and procedures.
Risk
Process deviations and compliance failures.
How to Avoid It
Implement a controlled Pharmaceutical Document Management System.
Learn More:
https://vmtspharmasoftware.com/documentmanagementsystem/
System changes occur without formal review or approval.
Risk
Uncontrolled modifications affecting validated states.
How to Avoid It
Document:
FDA Finding
Audit trails exist but are never reviewed.
Risk
Potential data manipulation goes undetected.
How to Avoid It
Establish periodic audit trail review procedures and document findings.
Administrators can modify records without oversight.
Risk
Unauthorized data changes.
How to Avoid It
Separate:
Organizations cannot restore critical records during inspections.
Risk
Permanent data loss.
How to Avoid It
Implement:
Employees are not trained on regulated systems.
Risk
User errors affecting compliance.
How to Avoid It
Track:
Former employees retain system access.
Risk
Unauthorized activity.
How to Avoid It
Conduct periodic access reviews and disable inactive accounts immediately.
Organizations cannot demonstrate compliance with ALCOA+ principles.
Risk
Regulatory action and inspection findings.
How to Avoid It
Ensure records are:
Validated systems are never reassessed.
Risk
Compliance gaps remain undetected.
How to Avoid It
Perform annual reviews covering:
FDA Finding
Organizations struggle to retrieve records during inspections.
Risk
Delayed audits and regulatory observations.
How to Avoid It
Maintain centralized systems capable of instantly producing:
What FDA Inspectors Typically Ask During Part 11 Audits
Quality and Compliance teams should be prepared to answer:
How are audit trails reviewed?
Who approves electronic signatures?
How is system validation maintained?
How are user permissions controlled?
Can deleted records be recovered?
How is data integrity monitored?
These questions appear frequently during regulatory inspections.
How Modern FDA Compliance Software Reduces Audit Risk
A modern Pharma QMS Software platform helps organizations:
Explore VMTS Quality Management System:
https://vmtspharmasoftware.com/quality-management-system/
Frequently Asked Questions
What is the most common FDA Part 11 observation?
Audit trail deficiencies and inadequate data integrity controls remain among the most frequently cited issues.
Does Excel comply with 21 CFR Part 11?
Spreadsheets alone typically lack audit trails, electronic signatures, and security controls required for compliance.
Is computer system validation mandatory?
Yes. Systems supporting regulated activities must be validated to demonstrate fitness for intended use.
What software supports Part 11 compliance?
Validated Pharma QMS Software and Document Management Systems help organizations manage compliance requirements effectively.
Conclusion
Many FDA observations related to 21 CFR Part 11 are preventable. Organizations that invest in validated systems, robust audit trails, document control, training management, and data integrity practices significantly reduce regulatory risk.
Rather than treating Part 11 as a documentation exercise, pharmaceutical companies should view it as a framework for ensuring trust, traceability, and compliance across all electronic records and systems.
Explore VMTS Pharma Software solutions:
In today’s highly regulated pharmaceutical industry, maintaining product quality and regulatory compliance requires more than just standard operating procedures (SOPs) and documentation. Pharmaceutical companies must
Best DMS Software for Pharmaceutical Industry in 2026 The pharmaceutical industry generates and manages massive volumes of critical documents every day, including SOPs, batch records,
Best Benefits of eQMS Pharma Software for Pharmaceutical Companies The pharmaceutical industry operates in a highly regulated environment where maintaining product quality, compliance, and data
The pharmaceutical industry operates under strict regulatory standards where audit readiness is essential for maintaining compliance, product quality, and business continuity. Regulatory agencies such as
VMT Soft Sol Pvt. Ltd. specializes in eQMS Software for the pharmaceutical industry. We simplify compliance, enhance efficiency, and ensure operational excellence.
# 8-3-167/A/52, 2nd Floor, Vani Nilayam, Vikaspuri, AG Colony Road, S R Nagar(PO), Hyderabad-500038.
Phone Number : +91-9866968830
